Advanz Pharma (OTCMKTS:CXRXF) and ANCHIANO THERAP/S (NASDAQ:ANCN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Advanz Pharma and ANCHIANO THERAP/S, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanz Pharma 0 0 0 0 N/A
ANCHIANO THERAP/S 0 3 0 0 2.00

ANCHIANO THERAP/S has a consensus price target of $16.00, indicating a potential upside of 981.08%. Given ANCHIANO THERAP/S’s higher probable upside, analysts clearly believe ANCHIANO THERAP/S is more favorable than Advanz Pharma.

Profitability

This table compares Advanz Pharma and ANCHIANO THERAP/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Advanz Pharma -39.13% -191.06% -2.75%
ANCHIANO THERAP/S N/A -54.04% -33.83%

Insider & Institutional Ownership

7.5% of ANCHIANO THERAP/S shares are held by institutional investors. 6.9% of ANCHIANO THERAP/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Advanz Pharma and ANCHIANO THERAP/S’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Advanz Pharma $508.32 million 0.30 -$196.02 million N/A N/A
ANCHIANO THERAP/S N/A N/A -$27.12 million ($3.46) -0.43

ANCHIANO THERAP/S has lower revenue, but higher earnings than Advanz Pharma.

Summary

ANCHIANO THERAP/S beats Advanz Pharma on 6 of the 9 factors compared between the two stocks.

About Advanz Pharma

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in Mississauga, Canada.

About ANCHIANO THERAP/S

Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.